bootstrap-your-bio-tech

How to Commercialize University Research

Mon, 14 Sep 2026 21:55:14 GMT

University research can create enormous scientific value without ever becoming a product. Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

1. Start with the Problem, Not the Technology

Academic discoveries are often described by mechanism, platform, assay, material, or technical novelty. Commercialization begins by identifying the problem the discovery could solve, who experiences that problem, and why the current alternatives are inadequate.

A single technology may have many possible applications. The first commercialization task is to choose a beachhead opportunity where the unmet need, technical fit, evidence requirements, and market pathway are attractive enough to justify focused development.

Who has the problem?
How is it solved today?
What is meaningfully better about the new approach?
What evidence would persuade a user, buyer, licensee, or investor?

2. Protect the Intellectual Property before Public Disclosure

For university-originated inventions, the technology-transfer office should be involved early. Publication, presentations, posters, grant disclosures, and conference activity can affect patent strategy. Researchers should understand invention disclosure requirements, ownership, patent filing status, and any third-party obligations before beginning commercial outreach.

3. Decide What Commercialization Path Fits the Asset

Not every university technology needs a startup. Some assets are better suited for licensing to an established company; others may need a new company to perform the development work required before industry will engage. The decision should be driven by the asset, market, development burden, partner appetite, and the research team's goals.

License directly when an established company can absorb the technology with relatively little additional de-risking.
Form a startup when substantial development is required and a focused company can create value before licensing or acquisition.
Use sponsored research, option agreements, or strategic collaborations when more evidence is needed before a full commercial commitment.

4. Build a Commercialization Evidence Plan

The experiments needed for publication are not always the experiments needed for commercialization. Work backward from the next external decision-maker and ask what data would reduce the risk that person cares about. That may include comparative performance, manufacturability, clinical workflow, regulatory evidence, reimbursement, scalability, or customer validation.

5. Match Funding to the Next Milestone

University translational funds, SBIR/STTR, disease foundations, state programs, accelerators, strategic partners, and private capital can all play roles. The objective is to use the least expensive capital that can credibly reach the next value-creating milestone, especially before giving up significant equity.

6. Build the Commercial Team around Gaps

The academic inventor does not need to become the CEO. Successful commercialization often requires a combination of scientific leadership, product development, regulatory, market, business-development, and financing expertise. Identify the capabilities required for the next stage and fill them deliberately.

BYB Takeaway

Planning to commercialize university research? Use BYB resources to map the path before the most expensive decisions are made.

What Is a Biotech Commercialization Plan?

Sun, 13 Sep 2026 21:55:14 GMT

A biotech commercialization plan is more than a market analysis or an investor deck. It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.

What a Commercialization Plan Should Answer

A useful plan forces the team to connect technical development with commercial outcomes. It should make the major assumptions visible so they can be tested before they become expensive.

What product are we actually building?
Who is the initial customer, user, patient, buyer, payer, or strategic partner?
What problem does the product solve better than existing alternatives?
What intellectual-property position will protect the opportunity?
What regulatory pathway and evidence requirements are likely?
How will the product be paid for or economically justified?
What technical and commercial milestones create the next increase in value?
What type of capital should fund each milestone?
What is the likely partnering, licensing, or exit strategy?

The Plan Should Be Milestone-Driven

Early-stage companies cannot predict every future event. A commercialization plan should therefore be built around staged decisions rather than false precision. Define the next several value inflection points, the evidence required to reach them, and the capital needed for each step.

Commercialization Planning Should Influence R&D

The most valuable plan changes what the team does in the laboratory, clinic, engineering program, or validation study. If customer, regulatory, reimbursement, or partner requirements are known early, the next study can be designed to answer both a scientific and a commercial question.

A Commercialization Plan Is Different from a Business Plan

A traditional business plan often describes the company. A commercialization plan focuses more directly on de-risking the asset: product definition, evidence, market pathway, regulatory strategy, reimbursement, IP, milestones, capital sequence, and partnering logic. It can later become the foundation for the business plan, grant commercialization section, pitch deck, and strategic roadmap.

Update It as Evidence Changes

Commercialization plans should evolve. A customer interview may change the use case. FDA feedback may change the validation plan. A strategic partner may identify a missing experiment. A financing environment may alter the optimal sequence. The plan is valuable because it provides a framework for incorporating new information without losing strategic direction.

BYB Takeaway

A biotech commercialization plan is the bridge between scientific progress and commercial value. It should show what must be proven next, why that proof matters, who will care, and what capital should be used to obtain it.

Before raising capital or forming a company, build the commercialization roadmap that explains what the money is supposed to accomplish.

How Much Validation Do You Need Before Raising Capital?

Sat, 12 Sep 2026 21:55:14 GMT

There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered. But the company does need enough evidence to make the remaining risk understandable, financeable, and appropriate for the type of investor being approached.

The Right Question Is Not “Do We Have Enough Data?”

A better question is: Have we reduced the risks that this investor expects to be reduced at this stage? A seed investor may accept early technical uncertainty that a later-stage fund would not. A strategic investor may care intensely about one validation experiment that a generalist investor barely understands.

Validation Should Support the Product Thesis

Investors want evidence that connects the science to the proposed product. The exact package depends on the asset, but early validation often needs to address several categories.

Reproducibility: Can the result be repeated reliably?
Relevance: Does the model, sample, population, or use environment resemble the intended application?
Differentiation: Is performance meaningfully better than the relevant alternative?
Translation: Is there a credible connection between the early result and the next development stage?
Commercial fit: Does the evidence support a problem and use case that customers or partners actually care about?

Raise after Meaningful Risk Reduction When Possible

If a modest non-dilutive award, translational grant, sponsored program, or founder-funded study can answer a major diligence question, completing that work first may improve valuation and terms. That is especially important when the missing validation is inexpensive relative to the dilution that an early equity round could require.

Do Not Over-Validate before Talking to Investors

Waiting for a “perfect” data package can also be a mistake. Investor conversations can reveal what different funds actually need to see, and those conversations can help prioritize experiments. Founders can begin relationship-building before a formal raise while being clear about the current stage and upcoming milestones.

Tie the Financing Ask to the Next Proof Point

An effective use of proceeds does not merely fund eighteen months of operations. It funds a defined set of activities that will create a more valuable company at the end of the runway.

What will be proven with this round?
What risk will be reduced?
What milestone will be reached?
Why will that milestone improve financing, licensing, regulatory, or partnering options?

BYB Takeaway

Raise when the company has enough validation to make the next risk worth financing—and when the capital will reach a milestone that materially improves the company's value or strategic options.

Before fundraising, identify the single validation gap most likely to weaken diligence or valuation and determine whether it can be closed first.

License Your Technology or Start a Biotech Company?

Fri, 11 Sep 2026 21:55:14 GMT

For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further. Neither path is inherently better. The right choice depends on how much work remains between the current research asset and something industry is ready to buy, license, or acquire.

When Direct Licensing Can Make Sense

Direct licensing is attractive when an established company already has the development capabilities, market access, regulatory infrastructure, manufacturing, or distribution needed to commercialize the invention—and when the technology is mature enough to compete for internal resources.

The commercial application is clear.
The asset fits an existing company's strategic priorities.
The remaining development can be absorbed by the licensee.
There is enough evidence for a partner to justify diligence and internal sponsorship.
The inventor prefers scientific participation over company-building.

When a Startup Can Create More Value

A startup may be necessary when the technology is too early for a traditional licensee, when substantial validation is required, or when a focused team can create a more valuable asset before partnering. The startup becomes a vehicle for concentrating capital, talent, and development around the technology.

Industry feedback is positive but consistently asks for more data.
The technology supports a differentiated product that requires focused development.
Non-dilutive funding can support early de-risking.
The opportunity may expand into multiple products or a platform.
Creating a development-ready asset could materially improve future licensing economics.

Compare the Hidden Costs of Both Choices

Licensing may require less founder time and capital, but the technology can receive less attention inside a large company or may command modest economics if it is very early. Starting a company can preserve more upside and control, but it introduces financing, governance, hiring, regulatory, operational, and dilution risk.

Use Partner Feedback as Evidence

Before forming a company solely because licensing outreach has been slow, ask prospective partners what is missing. If several companies identify the same validation gap, that is useful information. A startup can be designed specifically to close that gap and return to the market with a stronger asset.

Consider a Staged Path

The choice does not always have to be permanent. A team may form a startup, obtain a license or option from the university, use grants to generate validation data, and then partner or sell the company after a defined milestone. Conversely, a research collaboration or option agreement can sometimes test strategic interest before full company formation.

BYB Takeaway

License when the market is ready to absorb the asset. Start a company when focused de-risking can materially increase the technology's value, expand its strategic options, or make it partner-ready.

Do not start a biotech company simply because you have an invention. Start one when the company itself is the best vehicle for creating the next stage of value.

The Bootstrap Score™

Thu, 10 Sep 2026 21:55:14 GMT

Scientific quality is essential, but it is only one part of commercialization readiness. The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

What the Bootstrap Score™ Measures

The framework evaluates an opportunity across the areas that most often determine whether promising research can become a fundable, licensable, or buildable product. The point is not to create a perfect numerical prediction. It is to expose the weak links that can consume time, capital, and founder equity later.

Unmet need: Is the problem important enough that someone will change behavior, pay, license, adopt, or reimburse a solution?
Product definition: Is there a clear product concept, intended user, use setting, and target customer?
Evidence: Does the existing data answer commercially relevant questions, not only scientific ones?
Intellectual property: Is there a protectable position, freedom-to-operate strategy, or other defensibility?
Regulatory path: Is the likely FDA pathway and evidence burden understood at a useful level?
Reimbursement and economics: Is there a plausible route to payment and an attractive value proposition?
Team and execution: Are the capabilities needed for the next stage available internally or through advisors and partners?
Funding fit: Is the next source of capital matched to the next value-creating milestone?

How to Use the Score

Score each category from 1 to 5. A low score does not mean the science is weak; it means the commercialization plan contains unanswered questions. A high score should reflect evidence and decisions, not optimism.

The most useful result is usually not the total score. It is the pattern. A project can have extraordinary science and still be fragile because regulatory, reimbursement, customer, or IP assumptions have not been tested.

1 = largely unknown or untested
3 = working hypothesis with some supporting evidence
5 = clearly defined and supported by credible evidence

What Founders Should Do Next

Prioritize the lowest-scoring categories that could invalidate the business model or materially change the development plan. In many cases, one focused customer-discovery effort, regulatory assessment, IP review, or reimbursement analysis can prevent months of unfocused work.

BYB Takeaway

The purpose of the Bootstrap Score™ is not to tell you whether to start a company. It is to identify what must become true before the company deserves more capital, more founder time, or more dilution.

Want to pressure-test your commercialization readiness? Visit Bootstrap Your Biotech for commercialization resources and advisory support.

The Commercialization Gap™

Wed, 09 Sep 2026 21:55:14 GMT

Academic research and commercial development reward different outcomes. A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk. The distance between those two states is the Commercialization Gap™.

Why the Gap Exists

Academic programs are usually designed around scientific questions: Can an effect be demonstrated? Is a mechanism real? Is a hypothesis supported? Commercial programs must answer additional questions: Who needs the product? What would they pay for? What claims can be supported? What evidence would change adoption? How will the product be manufactured, regulated, reimbursed, and defended?

Publication evidence may not match regulatory evidence.
A technically elegant solution may not fit clinical workflow.
A broad platform story may not identify the first product.
Patent ownership may exist without a strong freedom-to-operate position.
Market size may look large while the reachable initial market is small.
Positive pilot data may not answer the question a strategic partner needs answered.

The Cost of Discovering the Gap Late

The later a team discovers a commercialization requirement, the more expensive it can be to correct. A study may need to be repeated with a different comparator. A diagnostic may need a different intended-use population. A device may need human-factors work that was not budgeted. A therapeutic may need additional CMC or translational evidence before a partner is willing to engage.

How to Close the Gap

Start with the future decision-maker and work backward. Identify who eventually must say yes—customer, clinician, payer, FDA reviewer, licensee, investor, strategic partner—and determine what evidence that person or organization will require.

Then design the next technical milestone to answer both a scientific question and a commercial question whenever possible.

Define the initial product and use case.
Interview customers and users before locking the development plan.
Map regulatory and reimbursement assumptions early.
Identify the next licensing or financing milestone.
Build studies that reduce specific commercial risks.

BYB Takeaway

The Commercialization Gap™ is rarely closed by adding a business plan after the research is finished. It is closed by deliberately shaping research and development around the decisions that must eventually be made.

BYB helps researchers and founders identify commercialization gaps before they become expensive.

The Valley of Dilution™

Tue, 08 Sep 2026 21:55:14 GMT

Biotech founders are often taught to fear the Valley of Death: the period between promising science and a financeable product. There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.

Why Premature Equity Is So Expensive

Equity is usually cheapest for the investor—and most expensive for the founder—when the company is early, uncertain, and dependent on future proof. If the same company can use grants, translational awards, sponsored research, disease-foundation funding, strategic support, or modest founder capital to reach a meaningful milestone first, its negotiating position may improve substantially.

Early valuation reflects unresolved scientific and commercial risk.
Large early rounds can create pressure to grow before product-market assumptions are tested.
Future financing may require increasingly large step-ups in valuation.
Founders can lose strategic flexibility when investors control major decisions.

What Should Be Funded before a Major Equity Round?

The objective is not to avoid venture capital. The objective is to use equity when it can accelerate a validated path rather than finance discovery of the path itself.

Initial customer and stakeholder discovery
Commercial use-case definition
Core IP strategy and license terms
Key proof-of-concept or validation milestones
Regulatory pathway assessment
Early reimbursement and market-access analysis
A credible development budget and financing plan

The Milestone-Value Relationship

A useful financing question is: What can we prove with the least dilutive capital that would materially change the company's value or financing options? That milestone may be a validated prototype, animal data, analytical performance, a regulatory interaction, a license, a pilot customer, or another asset-specific inflection point.

BYB Takeaway

Preserving equity is not the same as refusing investment. The goal is to cross the riskiest early milestones with the most capital-efficient funding available, then use institutional capital when it can create disproportionate value.

Before raising equity, ask: What milestone could we reach first that would make this company more valuable?

The Bootstrap Flywheel™

Mon, 07 Sep 2026 21:55:14 GMT

Biotech commercialization does not always move in a straight line from discovery to venture round. The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.

The Flywheel in Practice

Rather than beginning with 'How much money can we raise?', begin with 'What is the smallest high-value milestone we can achieve next?' Each completed milestone should generate new evidence or leverage that expands the company's choices.

Discovery becomes a defined product hypothesis.
Customer interviews sharpen the use case.
A sharper use case improves study design.
Better studies strengthen IP, regulatory, and partner discussions.
Stronger evidence improves grant and non-dilutive funding applications.
Non-dilutive funding creates more evidence without immediate dilution.
More evidence improves the terms of licensing, partnering, or financing.

Why Momentum Compounds

Commercial credibility is cumulative. A founder who can show a clear use case, stakeholder validation, an IP plan, regulatory thinking, and a milestone-driven budget is easier to fund than a founder presenting science alone. The same is true for strategic partners and university technology-transfer offices.

How to Keep the Flywheel Moving

The flywheel stalls when teams pursue activities that look impressive but do not reduce a meaningful risk. Every major expenditure should be connected to a specific question and a specific future decision.

What uncertainty does this activity reduce?
Who will care about the answer?
What milestone follows if the result is positive?
Does the work improve financing, licensing, regulatory, or market options?

BYB Takeaway

The Bootstrap Flywheel™ is about sequencing. Small wins become evidence; evidence becomes credibility; credibility expands funding choices; and better funding choices preserve strategic flexibility.

Build the next milestone to unlock the milestone after it.

Biotech Funding Sequence: What Money Should You Raise First?

Sun, 06 Sep 2026 21:55:14 GMT

The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.

A Bootstrap-First Sequence

There is no single financing path for every company, but many early programs benefit from moving from lower-cost, non-dilutive, or strategically aligned capital toward institutional equity as risk falls.

Founder, friends-and-family, or university translational support for initial formation and proof points
SBIR/STTR or other federal grants for feasibility and technical development
Disease-foundation, state, accelerator, or translational grants for targeted validation
SBIR/STTR Phase II or equivalent scale-up funding for development milestones
Strategic partnerships, sponsored development, licensing, or corporate collaboration
Family office, venture capital, or other institutional equity when larger-scale execution is justified

Match Money to Milestone

A grant is attractive because it is non-dilutive, but it may be slow, restricted, and milestone-specific. Strategic capital can validate the market but may come with rights that constrain future partners. Venture capital can move quickly and fund ambitious development, but it costs equity and often governance rights.

Questions to Ask before Every Raise

Financing should be designed around a value inflection point rather than a generic runway target.

What milestone will this capital achieve?
What uncertainty will that milestone remove?
Will achieving it materially improve valuation or partnering leverage?
Could a less dilutive source fund all or part of it?
How much runway is required to reach the next financeable event?

BYB Takeaway

Use the least expensive capital that can credibly achieve the next value-creating milestone. Then reconsider the financing strategy with a stronger asset and better information.

Capital should follow the commercialization roadmap—not substitute for one.

When Should a Biotech Startup Raise Venture Capital?

Sat, 05 Sep 2026 21:55:14 GMT

Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.

VC Makes Sense When Speed and Scale Matter

Equity financing can be the right choice when the company has a credible product path, the next milestones require substantial capital, and reaching them quickly has meaningful competitive or strategic value.

The product concept and initial indication are defined.
Core technical feasibility has been demonstrated.
The IP position is understood well enough for diligence.
The regulatory pathway is reasonably mapped.
The company can explain the market, customer, and value proposition.
There is a milestone-based use of proceeds tied to value creation.
The team can credibly execute the funded plan.

Signs You May Be Raising Too Early

An investor meeting should not be the first time a founder is forced to define the product, target customer, regulatory path, or capital required to reach a meaningful inflection point.

The pitch is primarily about the platform rather than the first product.
The financing ask is based on runway instead of milestones.
Customer discovery has not been performed.
Key license or IP terms are unresolved.
The regulatory route could materially change the development budget.
The company cannot explain what the next round would finance.

A Better Question than ‘Are We Ready for VC?’

Ask: If we raised equity today, would that capital accelerate a path we understand—or would it primarily pay us to discover what the path is? The first situation can justify institutional capital. The second often suggests more de-risking is needed.

BYB Takeaway

Raise venture capital when it can accelerate a defined, valuable development path—not simply because venture capital is available.

Use non-dilutive and milestone-driven resources to improve the terms of the equity you eventually raise.

What Is NIH TABA?

Fri, 04 Sep 2026 21:55:14 GMT

NIH Technical and Business Assistance—commonly called TABA—is designed to help SBIR and STTR recipients address product-development and commercialization needs that are often outside the core scientific aims of the award.

How Much Taba Funding Is Available?

Under NIH policy applicable to SBIR/STTR awards and supplements made on or after April 13, 2026, recipients may request up to $6,500 per Phase I project across all years and up to $50,000 per Phase II project across all years. NIH also describes up to $50,000 for a Phase IIB Strategic Breakthrough project. Availability can depend on the specific Institute, Center, and funding opportunity

What Can Taba Support?

NIH identifies a broad range of eligible technical and business activities. The best use is usually a clearly defined commercialization problem that requires expertise the company does not already have.

Market research and market validation
Regulatory planning
Manufacturing planning
Intellectual-property strategy and protections
Product sales and commercialization assistance
Cybersecurity assistance
Technical and business literature or databases
Participation in NIH I-Corps or similar training
Other activities consistent with reducing technical or commercialization risk

How Is Taba Requested?

NIH encourages companies to request TABA in the original SBIR/STTR application. The request is identified on the SBIR/STTR Information Form, the cost is labeled 'Technical Assistance' under Other Direct Costs, and the budget justification should explain the need and proposed use.

NIH also states that post-award TABA may be requested through an administrative supplement, subject to the discretion and prior-approval process of the awarding Institute or Center.

Taba Is Not Generic Overhead

A strong TABA request connects an outside activity to a specific development decision. 'Commercialization consulting' is vague. 'Develop a U.S. regulatory pathway assessment, competitor matrix, customer-discovery plan, and commercialization milestones to inform Phase II development' is much easier to evaluate.

BYB Takeaway

TABA is most valuable when it solves a defined commercialization problem and produces a concrete deliverable that improves the company's next technical, regulatory, market, or financing decision.

BYB can help founders define commercialization work packages that are specific enough to be useful and fundable.

Source Notes

NIH SEED, Technical and Business Assistance: https://seed.nih.gov/product-development-support/technical-business-assistance

NIH Notice NOT-OD-26-075, Policy changes to SBIR and STTR Discretionary TABA: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-075.html

How to Use TABA After an NIH SBIR Phase I Award

Thu, 03 Sep 2026 21:55:14 GMT

A Phase I award proves that NIH sees merit in the proposed technical work. It does not automatically answer the commercial questions needed for Phase II, licensing, strategic partnering, or private financing. TABA can be used to close some of those gaps.

First, Confirm Eligibility and Institute-Specific Process

NIH states that TABA is preferably requested in the original application, but recipients may request TABA funding after award through an administrative supplement. The awarding Institute or Center has discretion to accept or reject the request, so the first practical step is to contact the appropriate NIH Small Business Program Manager or grants contact before preparing a supplement.

Second, Define One or More Concrete Commercialization Needs

The strongest request is tied directly to decisions the company must make during or immediately after Phase I.

Which indication or beachhead market should be prioritized?
What is the likely FDA pathway and what evidence will be required?
What competitors and alternative approaches define the commercial landscape?
What IP risks or white-space opportunities should be evaluated?
What development milestones will make the program ready for Phase II or private capital?
Which strategic partners, licensees, customers, or investors are most relevant?

Third, Build a Deliverable-Driven Scope of Work

NIH guidance emphasizes describing the vendor, scope of work, and use of funds. A practical TABA scope should specify tasks, deliverables, schedule, and price rather than rely on broad advisory language.

Commercial landscape and competitor matrix
Regulatory pathway memo
Customer/stakeholder discovery plan and findings
Commercialization roadmap with prioritized milestones
Partner or financing target map
Manufacturing, cybersecurity, or other specialized development plan

Fourth, Connect Taba to Phase II Readiness

The most useful TABA work changes what the company does next. For example, market findings might change the initial indication; regulatory analysis might alter the validation study; partner feedback might define the data package required before outreach. Those connections should be explicit.

Administrative Supplement Basics

NIH's SEED FAQ indicates that post-award TABA can be requested through an administrative supplement and is subject to Institute or Center discretion and NIH prior-approval requirements. Confirm the exact submission instructions, budget treatment, timing, and required attachments with your awarding component before submitting.

BYB Takeaway

Treat TABA as a targeted de-risking budget, not an extra consulting allowance. The goal is to spend a small amount now to make a better Phase II, regulatory, partnering, or financing decision later.

Before submitting a TABA supplement, define the exact question, vendor deliverable, and decision the work will support.

Source notes

NIH SEED TABA FAQ: https://seed.nih.gov/faqs

NIH SEED, Creating a TABA request: https://seed.nih.gov/node/4222

NIH Notice NOT-OD-26-075: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-075.html

How to Commercialize a Medical Diagnostic

Wed, 02 Sep 2026 21:55:14 GMT

Diagnostics are deceptively difficult to commercialize because analytical performance alone does not create adoption. A successful diagnostic must be technically reliable, clinically meaningful, operationally usable, economically justified, and supported by an appropriate regulatory and reimbursement strategy.

1. Define the Intended Use before Perfecting the Assay

The same underlying technology can become very different products depending on population, specimen, setting, user, claim, and clinical decision. Those choices affect validation, regulatory classification, workflow, reimbursement, and market size.

Who is tested?
Why are they tested?
What specimen is used?
Where is the test performed?
Who orders and interprets it?
What clinical action changes because of the result?

2. Separate Analytical Validity from Clinical Value

Analytical performance—accuracy, precision, sensitivity, specificity, interference, reproducibility, stability—is necessary. Commercial adoption also depends on whether the result improves a clinically meaningful decision.

Build evidence around the comparator and outcome that matter to the intended user and payer, not simply the easiest study to publish.

3. Map the FDA Pathway Early

For IVDs, FDA classification and premarket requirements depend on device type and risk. Existing device types may follow 510(k), while a novel low- to moderate-risk device without a predicate may be eligible for De Novo classification. High-risk devices generally require PMA. When classification is uncertain, FDA resources, a Pre-Submission, or a 513(g) request can help clarify the pathway.

4. Build Reimbursement into Product Strategy

A test can be clinically useful and still fail commercially if no stakeholder has a reason to pay for it. Evaluate coding, coverage, payment, health-economic value, site-of-service economics, and who bears the cost versus who receives the benefit.

5. Validate Workflow and Adoption

Talk to laboratory directors, clinicians, administrators, payers, and procurement stakeholders. Understand sample logistics, turnaround time, instrumentation, training, reporting, integration, and the threshold for switching from the current standard.

6. Choose the Commercialization Model

Possible models include centralized testing, distributed kits, instrument-plus-consumable models, licensing, partnerships with established diagnostic companies, or strategic acquisition. The product design should fit the model, not the other way around.

BYB Takeaway

The best diagnostic commercialization plans begin with the clinical decision and work backward to the assay, evidence, regulatory path, reimbursement strategy, and business model.

Do not ask only, 'Does the test work?' Ask, 'What decision does it improve, and who will pay to improve that decision?'

Source notes

FDA, Overview of IVD Regulation: https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation

FDA, Laboratory Developed Tests FAQs: https://www.fda.gov/medical-devices/laboratory-developed-tests-faqs

How to Commercialize a Medical Device

Tue, 01 Sep 2026 21:55:14 GMT

Medical-device commercialization is an exercise in integration. Engineering, clinical evidence, regulatory strategy, human factors, quality systems, manufacturing, reimbursement, and customer workflow all interact. Decisions made in one area can create cost or delay in another.

1. Lock the Clinical Problem and User

A device should be designed around a specific user, use environment, and clinical problem. 'Surgeons' or 'hospitals' is not enough. Identify the procedure, workflow, setting, purchasing stakeholder, and measurable improvement.

2. Identify Classification and Regulatory Pathway

FDA generally reviews moderate-risk devices through 510(k) when an appropriate predicate exists; novel low- to moderate-risk devices may use De Novo; high-risk devices generally require PMA. Some low-risk devices are exempt from premarket review. The pathway influences evidence, design controls, timeline, and financing needs.

3. Design for Evidence, Usability, and Manufacturability

Prototype work should not optimize technical performance in isolation. Incorporate design inputs, risk management, human factors, verification and validation, sterilization or biocompatibility needs where applicable, and a path to scalable manufacturing.

4. Use FDA Interaction Strategically

When the pathway, testing plan, or clinical strategy contains meaningful uncertainty, the Q-Submission/Pre-Submission process can be used to seek FDA feedback before committing to expensive studies.

5. Validate the Buying Process

The person who uses the device may not control the purchase. Map the economic buyer, clinical champion, value-analysis committee, hospital administration, supply chain, distributor, or other decision-makers.

6. Plan Reimbursement and Economics

Determine whether the device is paid separately, bundled into a procedure, covered through an existing code, or dependent on a new payment pathway. Even when reimbursement is indirect, the economic value proposition must be clear.

7. Finance to Regulatory and Commercial Milestones

Build the budget around prototypes, verification, regulatory interaction, submission, clinical evidence, manufacturing transfer, and launch—not just monthly burn. Each financing round should reach a milestone that meaningfully reduces risk.

BYB Takeaway

A medical device is not commercially ready because the prototype works. It is ready when the product, evidence, regulatory pathway, manufacturing process, workflow, buyer, and economics fit together.

Design the commercialization system at the same time you design the device.

Source notes

FDA, Medical Device Safety and the 510(k) Clearance Process: https://www.fda.gov/medical-devices/510k-clearances/medical-device-safety-and-510k-clearance-process

How to Commercialize a Therapeutic

Mon, 31 Aug 2026 21:55:14 GMT

Therapeutics require long timelines and substantial capital, which makes early sequencing unusually important. The objective is not to eliminate risk before financing—it is to identify which risks must be reduced before the next source of capital or strategic partner will engage.

1. Start with the Target Product Profile

Define the initial indication, patient population, route, dosing concept, competitive standard, target efficacy, safety expectations, and differentiation. A platform may support many programs, but the first asset needs a specific product thesis.

2. Build Translational Evidence around a Partner’s Questions

Mechanistic novelty is not the same as development readiness. Strengthen the connection among target biology, disease relevance, pharmacology, biomarkers, exposure, efficacy, and safety. The exact evidence package depends on modality and indication.

3. Protect the Asset and Understand License Economics

Evaluate composition, use, method, platform, manufacturing, and other IP opportunities as appropriate. For university spinouts, license terms can materially affect future diligence, financing, sublicensing, and acquisition economics.

4. Bring CMC Forward

Chemistry, manufacturing, and controls can become a critical path surprisingly early. Develop a realistic plan for reproducibility, characterization, formulation, stability, scale-up, release testing, and supply appropriate to the stage.

5. Use Regulatory Strategy to Shape Development

FDA interactions such as pre-IND meetings can help sponsors discuss development questions before an IND. The best regulatory strategy is not a document prepared at the end; it is a set of assumptions that guide what work is performed, when, and to what standard.

6. Decide What to Build versus Partner

Some founders should build through IND or early clinical proof of concept. Others may maximize value by partnering earlier. The right point depends on capital needs, competitive timing, internal capabilities, partner appetite, and the evidence required to command acceptable terms.

7. Finance Inflection Points

Use grants, disease foundations, translational programs, strategic research support, and equity in combinations that fit the asset. Major capital should be tied to meaningful events such as candidate selection, IND-enabling completion, IND clearance, first-in-human data, or clinical proof of concept.

BYB Takeaway

Therapeutic commercialization is a sequence of risk-reduction decisions. The strongest teams know which question must be answered next, what evidence will answer it, and which source of capital should pay for that evidence.

Do not build the entire company plan around the science alone; build it around the next value inflection point.

Source notes

FDA, IND Meetings for Human Drugs and Biologics (guidance): https://www.fda.gov/media/70827/download

Biotech Regulatory Strategy Before Fundraising

Sat, 29 Aug 2026 21:55:14 GMT

Regulatory strategy is often treated as a later-stage task. For fundraising, that can be a costly mistake. Investors are not only evaluating whether the science is exciting; they are evaluating whether the development path is understandable and whether the financing ask is sufficient to reach the next meaningful milestone.

Regulatory Assumptions Drive the Budget

Device classification can determine whether a company is planning for exemption, 510(k), De Novo, or PMA. A diagnostic's intended use can change validation requirements. A therapeutic's IND-enabling package and CMC plan can shape millions of dollars of spending. If the pathway is wrong, the fundraising model can be wrong.

What Investors Want to See

Early companies do not need every regulatory question answered. They do need to demonstrate that the major pathway assumptions have been investigated and that uncertainty is acknowledged.

Product classification or development category
Likely submission or interaction pathway
Key preclinical, analytical, clinical, or validation requirements
Major regulatory risks and decision points
Planned FDA interactions where uncertainty is material
Budget and timeline implications

Use Regulatory Work to Improve Milestones

A credible regulatory plan turns a vague use of proceeds into a development plan. Instead of 'raise $4 million for product development,' a company can show what the financing will achieve, which regulatory gates will be crossed, and what evidence will exist at the end.

Do Not Overstate Certainty

Regulatory diligence is about credible assumptions, not pretending that FDA has agreed with a plan it has never reviewed. Clearly distinguish internal strategy, consultant interpretation, precedent, and actual agency feedback.

BYB Takeaway

Before fundraising, know enough about the regulatory path to explain what the money will accomplish, what could change the plan, and why the proposed milestones matter.

A regulatory strategy should improve the financing story because it improves the development story.

Customer Discovery for Biotech Founders

Fri, 28 Aug 2026 21:55:14 GMT

Biotech founders sometimes assume customer discovery is less relevant because the science is complex or the product is years from market. The opposite is often true. Long development cycles make early commercial mistakes more expensive.

Who Is the Customer?

In healthcare, the user, buyer, payer, beneficiary, and decision-maker may all be different. Customer discovery should map the ecosystem rather than interview one convenient stakeholder.

Clinicians and end users
Patients or caregivers where appropriate
Laboratory or technical operators
Hospital administrators and procurement
Payers and reimbursement experts
Pharma or strategic partners
Distributors or channel partners
Technology-transfer and licensing stakeholders

Ask about Behavior, Not Praise

'Would you use this?' produces weak evidence. Better questions uncover current workflow, unmet need, cost, decision criteria, switching barriers, and the consequences of the problem.

How is this problem handled today?
What is most frustrating or expensive about the current approach?
When does the problem become important enough to act?
Who approves a change?
What evidence would be required before adoption?
What would prevent use even if the technology worked?

Do Not Pitch during Discovery

The purpose is to learn, not to persuade. If the founder spends most of the call explaining the technology, the interview often confirms the founder's assumptions rather than testing them.

Turn Interviews into Development Decisions

Customer discovery becomes valuable when findings change something: the initial indication, product features, comparator, endpoint, workflow, price hypothesis, evidence plan, or business model.

Look for Patterns, Not Compliments

One enthusiastic expert is not a market. Repeated evidence across stakeholders is more important than a single strong reaction. Document assumptions before interviews and record what changed afterward.

BYB Takeaway

Customer discovery is an R&D activity for the business model. It should reduce commercial uncertainty just as experiments reduce scientific uncertainty.

The earlier you discover that the market needs something different, the cheaper it is to change.

Reimbursement Strategy for Diagnostics and Devices

Thu, 27 Aug 2026 21:55:14 GMT

Regulatory clearance allows a product to be marketed. Reimbursement determines whether someone can afford to adopt it at scale. For diagnostics and many medical devices, those are separate problems that should be developed in parallel.

The Four Reimbursement Questions

A practical reimbursement assessment begins with four connected questions.

Who pays?
What code or payment mechanism is used?
Under what conditions will the payer cover the product or associated procedure?
Is the payment sufficient to support adoption and the business model?

Coding Is Not Coverage

Having a billing code does not guarantee that a payer will cover the product, and coverage does not guarantee attractive payment. Founders should avoid using the word 'reimbursement' as if it were a single milestone.

Understand Site of Service

Economics can change depending on whether care occurs in a physician office, hospital outpatient department, inpatient setting, laboratory, ambulatory surgery center, or home. The same product can create different incentives in each environment.

Build the Value Proposition for the Payer and Provider

Clinical benefit matters, but economic evidence often matters too. A diagnostic may avoid an unnecessary procedure, shorten time to treatment, or improve therapy selection. A device may reduce operating time, complications, length of stay, readmissions, or resource use.

Reimbursement Can Change Product Strategy

If payment depends on a particular setting, code, test category, or clinical pathway, those constraints can influence intended use, trial design, price, launch sequence, and the customer you prioritize.

Plan Evidence before the Pivotal Study

Whenever possible, identify the clinical and economic data that payers and provider systems will eventually expect before the expensive validation program is locked.

BYB Takeaway

Do not treat reimbursement as a launch activity. Treat it as a product-development input that can affect evidence, pricing, workflow, adoption, and even the initial indication.

A cleared product without a payment pathway can still be commercially stranded.

When Should Biotech Founders Approach Pharma?

Wed, 26 Aug 2026 21:55:14 GMT

Founders often assume there is one ideal moment to approach pharma: after the data are complete. In reality, there are two different reasons to engage a strategic partner—learning and transacting—and the timing can be different for each.

Engage Early to Learn

Non-confidential conversations can help a founder understand how a potential partner thinks about the indication, competitive landscape, modality, evidence package, development stage, and internal priorities. Those conversations can shape the roadmap long before a formal partnering process.

Engage Later to Negotiate from Evidence

A formal licensing or acquisition discussion is stronger when the company can show a clear asset, credible IP, a defined indication, reproducible data, a development plan, and evidence aligned with the partner's risk threshold.

What Creates Strategic Interest?

Different companies have different thresholds, but the following factors commonly influence interest.

Strategic fit with pipeline and therapeutic area
Clear differentiation from current and emerging alternatives
Protectable IP and manageable diligence issues
Reproducible, decision-relevant data
Defined development and regulatory path
Commercial opportunity large enough to matter
A realistic deal structure and development plan

Do Not Confuse a Meeting with Validation

Business-development teams meet many companies. Interest, a follow-up call, or a confidentiality agreement is useful signal but is not the same as a term sheet. Track what evidence the partner says it needs next and use that information to prioritize development.

Create Competitive Tension Carefully

A structured outreach process can improve learning and negotiating leverage, but founders should avoid overstating partner interest or launching a broad process before the asset is ready for diligence.

BYB Takeaway

Approach pharma early enough to learn what matters, but try to negotiate after you have created the evidence that improves your leverage.

Ask strategic partners what would need to be true for the program to become actionable internally.

What Investors Expect Before Funding a Biotech Startup

Tue, 25 Aug 2026 21:55:14 GMT

Investors do not need every risk removed before they invest. They do need to understand the risks, why the opportunity is worth taking them, and how their capital will move the company to a more valuable state.

1. A Specific Product Thesis

Investors need to know what is being built, for whom, and why it matters. A platform can strengthen the story, but the first product or lead program usually anchors diligence.

2. Evidence That Supports the Thesis

Strong data should be reproducible, relevant to the intended product, and connected to the next development decision. Investors will ask what has been shown, what remains uncertain, and whether the planned work actually addresses the uncertainty.

3. Defensibility

Founders should be prepared to explain ownership, university licenses where applicable, patent strategy, competitive IP, trade secrets, know-how, data advantages, or other barriers to entry.

4. A Credible Regulatory and Development Path

The company should understand the likely pathway, major evidence requirements, key risks, and timing assumptions. Uncertainty is acceptable; unexamined uncertainty is not.

5. Commercial Relevance

Investors will test market need, competition, standard of care, adoption barriers, reimbursement or pricing logic, strategic exit possibilities, and whether the opportunity can become large enough for the fund's return requirements.

6. The Right Team for the Next Stage

An early company does not need every executive hired. It does need access to the capabilities required for the next milestones and enough self-awareness to know which gaps must be filled.

7. A Milestone-Based Financing Plan

The use of proceeds should answer: What does this round buy? What evidence or regulatory event exists when the money is spent? Why will the company be more valuable or financeable then?

8. A Believable Risk Story

The strongest pitch does not claim there is little risk. It identifies the major risks, shows how they are being reduced, and explains why the remaining risk is worth the potential return.

BYB Takeaway

Investors fund a risk-adjusted path to value—not a collection of scientific accomplishments. Connect the science to the product, the product to the market, and the financing to the next value inflection point.

Before investor outreach, make sure every major claim in the pitch connects to evidence, a plan, or an explicit assumption.